S100B and metabolic disease: This study reveals how signals from the suprachiasmatic nucleus coordinate the metabolic flexibility of BAT, through a adrenergic receptor ADRB3-S100B signaling axis, thereby identifying a new therapeutic target for metabolic disorders.